| Literature DB >> 33967700 |
Emma Louise Louth1,2, Rasmus Langelund Jørgensen3, Anders Rosendal Korshoej3, Jens Christian Hedemann Sørensen3, Marco Capogna1,2,4.
Abstract
Synapses in the cerebral cortex constantly change and this dynamic property regulated by the action of neuromodulators such as dopamine (DA), is essential for reward learning and memory. DA modulates spike-timing-dependent plasticity (STDP), a cellular model of learning and memory, in juvenile rodent cortical neurons. However, it is unknown whether this neuromodulation also occurs at excitatory synapses of cortical neurons in mature adult mice or in humans. Cortical layer V pyramidal neurons were recorded with whole cell patch clamp electrophysiology and an extracellular stimulating electrode was used to induce STDP. DA was either bath-applied or optogenetically released in slices from mice. Classical STDP induction protocols triggered non-hebbian excitatory synaptic depression in the mouse or no plasticity at human cortical synapses. DA reverted long term synaptic depression to baseline in mouse via dopamine 2 type receptors or elicited long term synaptic potentiation in human cortical synapses. Furthermore, when DA was applied during an STDP protocol it depressed presynaptic inhibition in the mouse but not in the human cortex. Thus, DA modulates excitatory synaptic plasticity differently in human vs. mouse cortex. The data strengthens the importance of DA in gating cognition in humans, and may inform on therapeutic interventions to recover brain function from diseases.Entities:
Keywords: dopamine; human cortical slices; layer 5 pyramidal neurons; spike timing dependent plasticity; synaptic inhibition
Year: 2021 PMID: 33967700 PMCID: PMC8102156 DOI: 10.3389/fncel.2021.668980
Source DB: PubMed Journal: Front Cell Neurosci ISSN: 1662-5102 Impact factor: 5.505
Donor patients attributes.
| Age | Sex | Histological diagnosis, tumor grade | Tumor IDH | Tumor localization, lateralization | Epilepsy, type | Anaesthesia | |
| 56–60 | Male | Glioblastoma, 4 | Wild type | Parietal, right | Yes, focal | Dexamethasone, Metaoxedrine/Phenylephrine, Prednisolone, Propofol, Remifentanil | |
| 76–80 | Male | Glioblastoma, 4 | Wild type | Temporal, right | No | Dexamethasone, Ephedrine, Fentanyl, Metaoxedrine/Phenylephrine, Propofol, Remifentanil | |
| 70–75 | Female | Tissue necrosis | N/A | Temporal, right | No | Dexamethasone,Metaoxedrine/Phenylephrine, Propofol, Remifentanil | |
| 50–55 | Male | Glioblastoma, 4 | Wild type | Temporal, right | Yes focal | Dexamethasone,Metaoxedrine/Phenylephrine, Propofol, Remifentanil | |
| 60–65 | Male | Glioblastoma, 4 | Wild type | Temporal, left | No | Ephedrine, Metaoxedrine/Phenylephrine, Noradrenalin, Prednisolone, Propofol, Remifentanil | |
| 60–65 | Female | Glioblastoma, 4 | Wild type | Occipital, right | Yes, generalized | Dexamethasone, Ephedrine, Fentanyl, Metaoxedrine/Phenylephrine, Noradrenalin, Propofol, Remifentanil | |
| 70–75 | Male | Glioblastoma, 4 | Wild type | Temporal, right | No | Ephedrine, Metaoxedrine/Phenylephrine, Prednisolone, Propofol, Remifentanil | |
| 70–75 | Female | Glioblastoma, 4 | Wild type | Frontal, left | No | Dexamethasone, Metaoxedrine/Phenylephrine, Ephedrine, Fentanyl, Propofol, Remifentanil | |
| 60–65 | Female | Glioblastoma, 4 | Wild type | Parietal, left | No | Dexamethasone, Metaoxedrine/Phenylephrine, Propofol, Remifentanil | |
| 40–45 | Male | Glioblastoma, 4 | Wild type | Parietal, left | No | Alfentanil, Dexamethasone, Metaoxedrine/Phenylephrine, Fentanyl, Propofol, Remifentanil, Propofol | |
| 56–60 | Male | Glioblastoma, 4 | Wild type | Temporal, left | Yes, generalized | Alfentanil, Dexamethasone, Metaoxedrine/Phenylephrine, Ephedrine, Fentanyl, Propofol, Remifentanil | |
| 56–60 | Male | Glioblastoma, 4 | Wild type | Temporal, left | Yes focal | Ephedrine, Fentanyl, Metaoxedrine/Phenylephrine, Propofol, Remifentanil, | |
| 60–65 | Male | Glioblastoma, 4 | Wild type | Temporal, right | No | Dexamethasone, Ephedrine, Metaoxedrine/Phenylephrine, Prednisolone, Propofol, Remifentanil | |
| 70–75 | Female | Glioblastoma, 4 | Wild type | Temporal, right | No | Dexamethasone, Ephedrine, Fentanyl, Metaoxedrine/Phenylephrine, Propofol, Remifentanil | |
| 55–60 | Male | Glioblastoma, 4 | Wild type | Temporal, right | No | Dexamethasone, Ephedrine, Fentanyl, Metaoxedrine/Phenylephrine, Propofol, Remifentanil | |
| 80–85 | Male | Glioblastoma, 4 | Wild type | Temporal, right | No | Cefruroxim, Dexamethasone, Ephedrine, Fentanyl, Metaoxedrine/Phenylephrine, Propofol, Remifentanil | |
| 65–70 | Female | Glioblastoma, 4 | Wild type | Temporal, right | No | Cefruroxim, Metaoxedrine/Phenylephrine, Propofol, Remifentanil | |
| 75–80 | Female | Gliobastoma, 4 | Wild type | Parietal, right | No | Cefruroxim, Ephedrine, Fentanyl, Metaoxedrine/Phenylephrine, Propofol, Remifentanil |
FIGURE 1STDP induction at varying timings in layer 5 cortical pyramidal neurons of mature adult mice and comparison to adult mice. (A) STDP induction at EPSP-AP pairing timings (Δτ) of –30 ms, –10 ms, and + 30 ms show no change in EPSP rising slope. At Δτ = + 10 ms neurons from mature adult mice (60–80 days old) exhibit t-LTD (*p = 0.008 vs. 100%) which was significantly different from adult mice (30–40 days old) (p = 0.0007). Neurons from adult mice exhibited no change (p = 0.094 vs. 100%). (B) The graph shows the time-course of the EPSP rising slope during the STDP experiments performed in both mature adult and adult mice. The gray bar in the graph illustrates the time of STDP induction. To the right, the STDP induction protocol timing is illustrated and below are example traces of EPSPs. The EPSPs were evoked at a rate of 0.14 Hz throughout the protocol. The baseline trace is the darker trace, the traces following STDP induction are the lighter traces; each trace is the average of 80 traces from the same recording. All data are shown as mean ± SEM. Number of neurons recorded in mature adult mice, n = 8 (4 prefrontal, 2 parietal and 2 temporal cortex), and in adult mice n = 6 (4 prefrontal, 1 parietal and 1 temporal cortex).
FIGURE 2Effect of dopamine on EPSP rising slope following STDP induction in mature adult mouse cortical layer 5 pyramidal neurons. (A) STDP induction at Δτ = –10 ms and + 10 ms EPSP-AP pairing timings with and without 20 μM dopamine application. EPSP rising slope with the –10 ms timing was not different between the control and dopamine group (p = 0.4). At the + 10 ms timing, EPSP rising slope showed a significant change (*p = 0.01) from t-LTD to no change. The time-course of the EPSP rising slope during the STDP experiment using the + 10 ms timing is shown in (B) and the –10 ms timing in (C). Dopamine bath application and the time of STDP induction are indicated by bars in the graphs. To the right, the STDP induction protocol timing is illustrated and below are example traces of EPSPs. The EPSPs were evoked at a rate of 0.14 Hz throughout the protocol. The baseline trace is the darker trace, the resultant trace following STDP induction is the lighter trace; each trace is the average of 80 traces from the same recording. All data are shown as mean ± SEM. For the –10 ms timing n = 6 and for the + 10 timing n = 8. Overall, data are from n = 28, 20 prefrontal, 4 parietal and 4 temporal recorded cells (Figure 2A); n = 16, 8 prefrontal, 4 parietal and 4 temporal recorded cells (Figure 2B); n = 12, all prefrontal recorded cells (Figure 2C).
FIGURE 3Optogenetically triggered DA release during STDP induction blocks EPSP rising time t-LTD in cortical layer 5 pyramidal neurons of mature adult mouse. (A) Scheme of the viral transfection (left) and the electrophysiological protocol for STDP induction (right). Briefly, ChR2 expressing fibers from dopaminergic neuron in the VTA (shown in green) were stimulated using blue light during the STDP induction protocol. (B) The time-course of the EPSP rising slope during the STDP experiment in both control and DatIREScre mice (left) and violin plots of the summary of the data, (right). Data demonstrate that optogenetically triggered release of DA (blue light pulses, 460 nm, ∼10 mW power) had a similar effect to bath applied DA (Dunn’s multiple comparison test, p = 0.99) where there is a significant difference between the control group and the DA exposed groups (Dunn’s multiple comparison test, control vs. bath application of DA: *p = 0.04, control vs. optogenetic DA: *p = 0.004). The EPSPs were evoked at a rate of 0.14 Hz throughout the protocol. In the middle example traces of EPSPs are shown. The baseline trace is the darker trace, the resultant trace following STDP induction is the lighter trace; each trace is the average of 80 traces from the same recording. All data are shown as mean ± SEM. For the optogenetic stimulation n = 6, while for the control and bath DA groups n = 8.
Basic electrophysiological properties of recorded neurons.
| Human | C57B/6 mice | DatIREScre mice | |
| 18 | 59 | 9 | |
| 65.3 ± 2.36 | 79.56 ± 1.78 | 72.78 ± 2.77 | |
| −68.17 ± 0.76 | −67.68 ± 0.63 | −68.91 ± 1.62 | |
| 135.7 ± 15.38 | 131.8 ± 5.58 | 146.0 ± 14.59 | |
| 209.1 ± 19.8 | 174.7 ± 8.10 | 159.0 ± 21.49 | |
| 1.13 ± 0.01 | 1.10 ± 0.02 | 1.09 ± 0.03 | |
| 105.4 ± 1.70 | 107.8 ± 1.21 | 108.5 ± 2.01 |
FIGURE 4DA potentiates baseline EPSP rising time after Δτ = + 10 ms STDP protocol in adult human cortical layer 5 pyramidal neurons. Left, the time-course of the EPSP rising slope after Δτ = + 10 ms STDP induction protocol. Middle, the STDP induction protocol timing is illustrated and below are example traces of EPSPs. The EPSPs were evoked at a rate of 0.14 Hz throughout the protocol. The baseline trace is the darker trace, the resultant trace following STDP induction is the lighter trace; each trace is the average of 80 traces from the same recording. Right, violin plots of summary of the results showing a significant difference between EPSP rising slope with and without DA application during STDP induction (*p = 0.0003). All data are shown as mean ± SEM. For the control group n = 7 and for the DA group n = 8. Overall, data are obtained from 15 neurons of human neocortex, 10 temporal, 4 parietal, 1 occipital in control and DA.
FIGURE 5DA reduces IPSC rising slope after Δτ = + 10 ms STDP protocol in cortical layer 5 pyramidal neurons of mature adult mice but not humans. Effect of DA on IPSC rising slope following STDP induction in adult mouse (A) and human (B) pyramidal neurons. Left, the time-course of the IPSC rising slope after Δτ = + 10 ms STDP timing protocol. Middle, the STDP induction protocol timing is illustrated and below are example traces of IPSCs. The IPSCs were evoked at a rate of 0.14 Hz throughout the protocol. The baseline trace is the darker trace, the resultant trace following STDP induction is the lighter trace; each trace is the average of 80 traces from the same recording. Right, violin plots showing summary of the results. DA significantly reduced the IPSC rising slope after STDP induction in neurons recorded from mature adult mice (*p = 0.001, n = 8), but not from humans (p = 0.6, n = 7). All data are shown as mean ± SEM. Overall, data are obtained from 16 neurons of mouse neocortex, 8 prefrontal, 4 temporal and 4 parietal, and from 14 neurons of human neocortex, 12 temporal and 2 frontal.